Magnus Tobiasson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BLOOD. 2024;144(11):1221-1229
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko M; Bernard E; Creignou M; Domenico D; Farina A; Arango Ossa JE; Kosmider O; Hasserjian R; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Gurnari C; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Sander B; Orna E; Zoldan K; Eder LN; Sperr WR; Thalhammer R; Ganster C; Adès L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Beck DB; Hellström-Lindberg E; Papaemmanuil E
Article: JOURNAL OF INTERNAL MEDICINE. 2024;296(1):53-67
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
Creignou M; Bernard E; Gasparini A; Tranberg A; Todisco G; Moura PL; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Elena C; Ferrari J; Galli A; Pozzi S; Malcovati L; Edgren G; Crowther MJ; Jaedersten M; Papaemmanuil E; Hellstroem-Lindberg E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(12):1378-1390
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Lundstrom LY; von Bahr L; Baltzer-Sollander K; Jadersten M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellstrom-Lindberg E
Article: BLOOD. 2024;143(11):953-966
Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation
Dimitriou M; Mortera-Blanco T; Tobiasson M; Mazzi S; Lehander M; Hoegstrand K; Karimi M; Walldin G; Jansson M; Vonlanthen S; Ljungman P; Langemeijer S; Yoshizato T; Hellstroem-Lindberg E; Woll PS; Jacobsen SEW
Article: CANCER RESEARCH COMMUNICATIONS. 2024;4(2):365-377
Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roue G; Valcarcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellstrom-Lindberg E; Sole F; Esteller M
Journal article: BLOOD. 2023;142:6039
New Assay Technology and Utility of Peripheral Blood Vs Bone Marrow for Molecular MRD in AML and MDS
Tobiasson M; Bosaeus L; Cavelier L; Chen L
Journal article: BLOOD. 2023;142:4587
Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes
Rombaut D; Tekath T; Sandmann S; Crouch S; De Graaf AO; Kosmider O; Tobiasson M; Lennartsson A; Van der Reijden BA; Park S; D'Aveni M; Slama B; Clappier E; Fenaux P; Ades L; De Loosdrecht AAV; Mc Langemeijer S; Symeonidis AS; Cermak J; Preudhomme C; Savic A; Germing U; Stauder R; Bowen DT; Van Marrewijk CJ; Bernard E; Smith A; Painter D; De Witte TJM; Lindberg EH; Varghese J; Dugas M; Martens JHA; Malcovati L; Jansen JH; Fontenay M
Journal article: BLOOD. 2023;142:1862
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko M; Bernard E; Creignou M; Domenico D; Farina A; Ossa JEA; Kosmider O; Hasserjian R; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Gurnari C; Follo MY; Thol F; Zamora L; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Beck DB; Lindberg EH; Papaemmanuil E
Journal article: BLOOD. 2023;142:997
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard E; Hasserjian R; Greenberg PL; Ossa JEA; Creignou M; Nannya Y; Tuechler H; Medina-Martinez JS; Levine MF; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Sirenko M; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Lindberg EH; Papaemmanuil E
Article: CLINICAL CANCER RESEARCH. 2023;29(20):4256-4267
Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
Todisco G; Creignou M; Bernard E; Bjorklund A-C; Moura PL; Tesi B; Mortera-Blanco T; Sander B; Jansson M; Walldin G; Barbosa I; Reinsbach SE; Hofman IJ; Nilsson C; Yoshizato T; Dimitriou M; Chang D; Olafsdottir S; Larsson SV; Tobiasson M; Malcovati L; Woll P; Jacobsen SEW; Papaemmanuil E; Hellstroem-Lindberg E
Journal article: HEMASPHERE. 2023;7(Suppl):e790629d
P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI‐CENTER PROSPECTIVE COHORT STUDY
Tesi B; Eriksson A; Baskin B; Lazarevic V; Deneberg S; Höglund M; Fogelstrand L; Ungerstedt J; Pandzic T; Tobiasson M; Garelius HG; Kuchinskaya E; Persson F; Ågerstam H; Uggla B; Hallböök H; Fioretos T; Thuresson A; Lehmann S; Ladenvall C; Barbany G; Vennström L; Ejerblad E; Cavelier L; Cammenga J; Jädersten M; Lindberg EH; Baliakas P
Article: BLOOD ADVANCES. 2023;7(14):3624-3636
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemanuil E; Miyazaki Y; Hellstrom-Lindberg E; Ogawa S
Article: BLOOD. 2023;142(1):73-89
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Journal article: LEUKEMIA RESEARCH. 2023;128:107119
EARLY TRANSFUSION PATTERNS PREDICT OUTCOMES INDEPENDENTLY OF IPSS-M SCORE IN MYELODYSPLASTIC SYNDROMES
Creignou M; Bernard E; Crowther M; Tranberg A; Todisco G; Moura P; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Edgren G; Jadersten M; Papaemmanuil E; Hellstrom-Lindberg E
Article: LAKARTIDNINGEN. 2022;119:22024
[Two cases of VEXAS syndrome].
Gunnarsson K; Vivar Pomiano N; Tesi B; Tobiasson M; Creignou M; Ungerstedt J
Article: NEJM EVID. 2022;1(7):evidoa2200008
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
Journal article: HEMASPHERE. 2022;6:68-69
S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Sollander K; Ejerblad E; Kittang AO; Olesen G; Werlenius O; Björklund A; Wiggh J; lindholm C; Lorentz F; Rasmussen B; Cammenga J; Weber D; Grönnås D; Dimitriou M; Kytölä S; Walldin G; Ljungman P; Groenbeck K; Mielke S; Jacobsen SE; Ebeling F; Cavelier L; Friis LS; Dybedal I; Hellström‐Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2022;57(4):598-606
Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study
Lindholm C; Olofsson E; Creignou M; Nilsson L; Garelius HG; Cammenga J; Ljungman P; Ejerblad E; Tobiasson M
Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2021;23(3):347-357
Multicenter Next-Generation Sequencing Studies between Theory and Practice Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data
Sandmann S; de Graaf AO; Tobiasson M; Kosmider O; Abaigar M; Clappier E; Galli A; van der Reijden BA; Malcovati L; Fenaux P; Diez-Campelo M; Fontenay M; Hellstrom-Lindberg E; Jansen JH; Dugas M
Journal article: BLOOD. 2020;136:5-6
Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B
Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Olsson D; Ejerblad E; Kittang AO; Olesen G; Werlenius O; Bjorklund AT; Lorentz F; Rasmussen BEH; Cammenga J; Weber D; Dimitriou M; Kytola S; Walldin G; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Friis LS; Dybedal I; Lindberg EH
Journal article: BLOOD. 2020;136(Supplement 1):38-40
Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms
Makishima H; Nannya Y; Takeda J; Momozawa Y; Saiki R; Yoshizato T; Atsuta Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Nagata Y; Shiozawa Y; Onizuka M; Chiba K; Tanaka H; Kakiuchi N; Ochi Y; Ueno H; Itonaga H; Kanda Y; Sanada M; Kon A; Miyazaki Y; Horibe K; Creignou M; Tobiasson M; Tsurumi H; Kasahara S; Polprasert C; Lindberg EH; Takaori AK; Kiguchi T; Cazzola M; Matsuda F; Ohyashiki K; Maciejewski JP; Haferlach T; Kamatani Y; Kubo M; Miyano S; Ogawa S
Journal article: BLOOD. 2020;136(Supplement 1):12-13
Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.
Nannya Y; Tobiasson M; Sato S; Bernard E; Creignou M; Zhao L; Takeda J; Shiraishi Y; Chiba K; Tanaka H; Tsurumi H; Kasahara S; Taguchi M; Takaori AK; Ohyashiki K; Makishima H; Yoshida K; Naoe T; Miyano S; Miyazaki Y; Papaemmanuil E; Lindberg EH; Ogawa S
Journal article: BLOOD. 2020;136(Supplement 1):29
Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints
Malcovati L; Crouch S; De Graaf AO; Sandmann S; Tobiasson M; Kosmider O; van der Reijden BA; Painter D; Van de Loosdrecht AA; Symeonidis A; Cermak J; Clappier E; Preudhomme C; Stauder R; Mittelman M; Germing U; Bowen D; Fenaux P; Van Marrewijk C; Smith A; Dugas M; Lindberg EH; de Witte TM; Fontenay M; Jansen J
Article: NATURE MEDICINE. 2020;26(10):1549-1556
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Article: LEUKEMIA. 2019;33(2):522-527
Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes
Ryden J; Edgren G; Karimi M; Walldin G; Tobiasson M; Wikman A; Hellstrom-Lindberg E; Hoglund P
Article: ONCOLOGIST. 2018;23(2):159-170
Azacitidine in Lower-Risk Myelodysplastic Syndromes: AMeta-Analysis of Data from Prospective Studies
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Article: BLOOD. 2017;130(7):881-890
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellstrom-Lindberg E
Article: CELL REPORTS. 2017;20(3):572-585
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
Unnikrishnan A; Papaemmanuil E; Beck D; Deshpande NP; Verma A; Kumari A; Woll PS; Richards LA; Knezevic K; Chandrakanthan V; Thoms JAI; Tursky ML; Huang Y; Ali Z; Olivier J; Galbraith S; Kulasekararaj AG; Tobiasson M; Karimi M; Pellagatti A; Wilson SR; Lindeman R; Young B; Ramakrishna R; Arthur C; Stark R; Crispin P; Curnow J; Warburton P; Roncolato F; Boultwood J; Lynch K; Jacobsen SEW; Mufti GJ; Hellstrom-Lindberg E; Wilkins MR; MacKenzie KL; Wong JWH; Campbell PJ; Pimanda JE
Article: ONCOTARGET. 2017;8(17):28812-28825
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grovdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
Article: ONCOTARGET. 2016;7(16):22103-22115
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
Article: CANCER CELL. 2014;25(6):794-808
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Woll PS; Kjallquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Goehring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellstrom-Lindberg E; Linnarsson S; Jacobsen SEW
Article: BLOOD CANCER JOURNAL. 2014;4(3):e189
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
Tobiasson M; Dybedahl I; Holm MS; Karimi M; Brandefors L; Garelius H; Grovdal M; Hogh-Dufva I; Gronbaek K; Jansson M; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Mollgard L; Hellstrom-Lindberg E
Journal article: BLOOD. 2013;122(21):4195
Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells
Woll P; Kjällquist U; Chowdhury O; Erlandsson R; Doolittle H; Ngara M; Anderson K; Giannoulatou E; Taylor S; Deng Q; Mead AJ; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Josefsen D; Kvalheim G; Göhring G; Schlegelberger B; Tobiasson M; Holm MS; Hokland P; Fenaux P; Nerlov C; Dybedal I; Nilsson L; Sandberg R; Hellström-Lindberg E; Linnarsson S; Jacobsen SEW
Journal article: BLOOD. 2011;118(21):3798
Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,
Tobiasson M; Brandefors L; Dybedal I; Garelius H; Grövdal M; Dufva IH; Kjeldsen L; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Möllgård L; Hellström-Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2011;46(5):719-726
Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT
Tobiasson M; Olsson R; Hellstrom-Lindberg E; Mattsson J
Article: MEDICAL ONCOLOGY. 2010;27(1):105-107
High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio.
Tobiasson M; Alyass B; Söderlund S; Birgegård G
Visa fler

Alla övriga publikationer

Editorial comment: HAEMATOLOGICA. 2023;108(7):1968-1971
Omalizumab alleviates pruritus in myeloproliferative neoplasms
Landtblom AR; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jadersten M
Conference publication: LEUKEMIA RESEARCH. 2023;128:107124
POST-AZACITIDINE CLONE SIZE PREDICTS LONG-TERM OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS
Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakicuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemmanuil E; Miyazaki Y; Hellstrom-Lindberg E; Ogawa S
Conference publication: LEUKEMIA RESEARCH. 2023;128:107227
COMPARISON OF MRD-MARKERS USING MUTATION-SPECIFIC DDPCR IN BONE MARROWAND PERIPHERAL BLOOD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS
Lindholm C; Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Kittang AO; Werlenius O; Wiggh J; Lorentz F; Rasmussen B; Cammenga J; Weber D; Moen AE; Lundstrom LY; Von Bahr L; Dimitriou M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SE; Ebeling F; Cavelier L; Friis LS; Dybedal I; Hellstrom-Lindberg E
Conference publication: LEUKEMIA RESEARCH. 2023;128:107146
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard E; Hasserjian R; Greenberg P; Ossa JA; Creignou M; Nannya Y; Tuechler H; Medina-Martinez J; Levine M; Jadersten M; Germing U; Sanz G; Van De Loosdrecht A; Kosmider O; Follo M; Thol F; Zamora L; Pinheiro R; Pellagatti A; Elias H; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta M; Fenaux P; Belickova M; Savona M; Klimek V; Santos F; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen J; Cervera-Zamora J; Gattermann N; Ebert B; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellstrom-Lindberg E; Papaemmanuil E
Preprint: BIORXIV. 2023
Dysregulated expression of Hoxa1 isoforms in hematopoietic stem and progenitor cells causes myelodysplastic syndromes
Tan S; Joseph C; Chalk AM; Hendy J; Fabb S; Schleibs K; Lee SC; Tjin G; Grace CS; Madugalle V; Smeets MF; Maluenda AC; Rice KL; Baker EK; Nandurkar H; Slape CI; Parker MW; Unnikrishnan A; Mufti GJ; Tobiasson M; Hellstrom-Lindberg E; Pimanda JE; Gudas LJ; Holien JK; Walkley CR; Wall M; Purton LE
Conference publication: BLOOD. 2022;140:9785-9788
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko M; Bernard E; Beck DB; Creignou M; Domenico D; Farina A; Arango JE; Kosmider O; Hasserjian RP; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Follo MY; Thol FR; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; de Souza Santos FP; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Hellstrom-Lindberg E; Papaemmanuil E
Meeting abstract: BLOOD. 2022;140:6968-6970
Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes
Creignou M; Bernard E; Crowther M; Tranberg A; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Rasmussen BEH; Lorenz F; Todisco G; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Edgren G; Jadersten M; Papaemmanuil E; Hellstrom-Lindberg E
Letter: BLOOD ADVANCES. 2022;6(16):4705-4709
The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
Hofman IJF; Mortera-Blanco T; Moura PL; Vestlund J; Larsson SV; Elvarsdottir EM; Walldin G; Tobiasson M; Sander B; Dimitriou M; Jacobsen S-EW; Woll PS; Jadersten M; Hellstrom-Lindberg E
Letter: LEUKEMIA. 2022;36(5):1436-1439
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
Rasmussen B; Gohring G; Bernard E; Nilsson L; Tobiasson M; Jadersten M; Garelius H; Dybedal I; Gronbaek K; Ejerblad E; Lorenz F; Flogegard M; Marcher CW; oster Fernstrom A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Norgaard JM; Saft L; Mollgard L; Hellstrom-Lindberg E
Letter: LEUKEMIA AND LYMPHOMA. 2022;63(3):755-758
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation
Jadersten M; Boriskina K; Lindholm C; Westrom S; Cavelier L; Hellstrom-Lindberg E; Mielke S; Tobiasson M
Preprint: RESEARCH SQUARE. 2021
Post-azacitidine clone size predicts long-term clinical outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
Ogawa S; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemmanuil E; Miyazaki Y; Hellstrom-Lindberg E
Corrigendum: NATURE MEDICINE. 2021;27(5):927
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Letter: BLOOD. 2021;137(9):1260-1263
Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder
Klimkowska M; Nannya Y; Gran C; Mansson R; Douagi I; Ogawa S; Nahi H; Tobiasson M
Corrigendum: NATURE MEDICINE. 2021;27(3):562
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Conference publication: LEUKEMIA RESEARCH. 2021;108:S7-S8
MYELOID NEOPLASMS WITH GERMLINE AND SOMATIC DDX41 MUTATIONS
Makishima H; Nannya Y; Momozawa Y; Gurnari C; Kulasekararaj A; Yoshizato T; Takeda J; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Saiki R; Yoshida K; Shiraishi Y; Nagata Y; Onizuka M; Nakagawa M; Itonaga H; Kanda Y; Miyazaki Y; Sanada M; Tsurumi H; Kasahara S; Kondo-Takaori A; Ohyashiki K; Kiguchi T; Matsuda F; Jansen J; Papaemmanuil E; Creignou M; Tobiasson M; Hellstrom-Lindberg E; Polprasert C; Malcovati L; Cazzola M; Haferlach T; Maciejewski J; Kamatani Y; Miyano S; Ogawa S
Review: HAEMATOLOGICA. 2020;105(7):1765-1779
Myelodysplastic syndromes: moving towards personalized management
Hellstrom-Lindberg E; Tobiasson M; Greenberg P
Preprint: BIORXIV. 2019
Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Conference publication: BLOOD. 2019;134:4246
Molecular Characteristics That Predict Response to Azacitidine Therapy
Nannya Y; Tobiasson M; Bernard E; Sato S; Creignou M; Takeda J; Zhao L; Shiraishi Y; Chiba K; Tanaka H; Tsurumi H; Kasahara S; Taguchi M; Takaori AK; Ohyashiki K; Makishima H; Yoshida K; Naoe T; Miyazaki Y; Miyano S; Papaemmanuil E; Lindberg EH; Ogawa S
Conference publication: BLOOD. 2019;134:675
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Bernard E; Nannya Y; Yoshizato T; Hasserjian RP; Saiki R; Shiozawa Y; Devlin SM; Tuechler H; Sarian A; Malcovati L; Sole F; Haase D; Creignou M; Levine M; Germing U; Cargo C; Zhang Y; Medina J; Ossa JEA; Schanz J; van de Loosdrecht A; Jadersten M; Bennett JM; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Klimek VM; Savona MR; Belickova M; Ganster C; Ades L; Della Porta MG; Smith A; Werner Y; Patel MA; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton K; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Lindberg EH; Ogawa S; Papaemmanuil E
Letter: LEUKEMIA AND LYMPHOMA. 2019;60(13):3316-3319
Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission
Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
Review: JOURNAL OF INTERNAL MEDICINE. 2019;286(1):41-62
Treatment of myelodysplastic syndrome in the era of next-generation sequencing
Tobiasson M; Kittang AO
Conference publication: HAEMATOLOGICA. 2016;101:157-158
INTEGRATIVE GENOMICS IDENTIFIES THE MOLECULAR BASIS OF RESISTANCE TO AZACITIDINE THERAPY IN MYELODYSPLASTIC SYNDROMES
Unnikrishnan A; Papaemmanuil E; Beck D; Verma A; Kumari A; Woll P; Richards L; Knezevic K; Chandrakanthan V; Thoms J; Tursky M; Huang Y; Ali Z; Olivier J; Galbraith S; Kulasekararaj A; Tobiasson M; Karimi M; Pellagatti A; Wilson S; Lindeman R; Young B; Ramakrishna R; Arthur C; Stark R; Crispin P; Curnow J; Warburton P; Roncolato F; Boultwood J; Lynch K; Jacobsen S; Mufti G; Hellstrom-Lindberg E; MacKenzie K; Wong J; Campbell P; Pimanda J
Conference publication: HAEMATOLOGICA. 2016;101:70
MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS
Tobiasson M; Ali HA; Lennartsson A; Katayama S; Marabita F; Karimi M; Khrjutskhov K; Einarsdottir E; Jansson M; Ben Azenkoud A; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
Conference publication: BLOOD. 2015;126(23):710
An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML
Unnikrishnan A; Papaemmanuil E; Beck D; Verma A; Kumari A; Richards LA; Knezevic K; Chandrakanthan V; Thoms JAI; Tursky ML; Huang Y; Galbraith S; Kulasekararaj AG; Tobiasson M; Woll PS; Pellagatti A; Wilson SR; Lindeman R; Boultwood J; Lynch K; Jacobsen SE; Mufti GJ; Hellstrom-Lindberg E; Mackenzie KL; Wong JWH; Campbell PJ; Pimanda JE
Conference publication: BLOOD. 2015;126(23):2839
Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy
Tobiasson M; MeLornan D; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj AG; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S69
IN VITRO AZACITIDINE CULTURE INDUCES DNA DEMETHYLATION AND INCREASED MRNA-LEVELS IN PRIMARY MDS PROGENITOR CELLS
Abdulkadir H; Tobiasson M; Lennartsson A; Katayama S; Marabita F; Karimi M; Qu Y; Einarsdottir E; Govdal M; Jansson M; Ben Azenkoud A; Lehmann S; Ekwall K; Kere J; Hellstom-Lindberg E; Ungerstedt J
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S153
DEVELOPMENT AND IMPLEMENTATION OF A NEW BIOBANK SYSTEM
Jansson M; Walldin G; Ben Azenkoud A; Dimitriou M; Karimi M; Tobiasson M; Jadersten M; Tapia J; Lindberg EH
Corrigendum: CANCER CELL. 2015;27(4):603-605
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo (vol 25, pg 794, 2014)
Woll PS; Kjaellquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Goehring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellstroem-Lindberg E; Linnarsson S; Jacobsen SEW
Thesis / dissertation: 2015
Clinical and molecular effects of azacitidine in the myelodysplastic syndromes
Tobiasson, Magnus
Conference publication: BLOOD. 2014;124(21):4601
Identification of a Prognostic Gene Expression Signature for AZA Response in MDS and CMML Patients
Unnikrishnan A; Beck D; Verma A; Richards LA; Thoms JAI; Kumari A; Galbraith S; Kulasekararaj A; Tobiasson M; Woll PS; Pellagatti A; Papaemmanuil E; Wilson SR; Lindeman R; Campbell PJ; Boultwood J; Lynch K; Jacobsen SEW; Mufti GJ; Hellstrom-Lindberg E; MacKenzie KL; Wong JWH; Pimanda JE
Conference publication: BLOOD. 2014;124(21):4613
Mutations in Histone Modulators and HOXA5 Methylation Levels Affects Survival in Azacitidine Treated MDS Patients
Tobiasson M; Karimi M; Dimitriou M; Qu Y; Lennartsson A; Ali HA; Unnikrishnan A; Jadersten M; Jansson M; Ben Azenkoud A; Pimanda JE; Ekwall K; Ungerstedt J; Lehmann S; Hellstrom-Lindberg E
Corrigendum: CANCER CELL. 2014;25(6):861
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo (vol 25, pg 794, 2014)
Woll PS; Kjaellquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Goehring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellstroem-Lindberg E; Linnarsson S; Jacobsen SEW
Letter: LEUKEMIA. 2014;28(2):411-413
Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation
Grovdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellstrom-Lindberg E
Conference publication: BLOOD. 2012;120(21):2394
Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine
Treppendahl MB; Tobiasson M; Aggerholm A; Karimi M; Silkjaer T; Friis LS; Andersen MK; Kjeldsen L; Holm MS; Hellstrom-Lindberg E; Gronbaek K
Conference publication: HAEMATOLOGICA. 2012;97:140-141
EVALUATION OF AZACITIDINE IN TRANSFUSION-DEPENDENT, EPO-REFRACTORY PATIENTS WITH LOWER-RISK MDS
Tobiasson M; Brandefors L; Dybedahl I; Garelius H; Grovdal M; Hogh-Dufva I; Kjeldsen L; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Mollgard L; Hellstrom-Lindberg E
Conference publication: BLOOD. 2011;118(21):1622-1623
Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome
Tobiasson M; Brandefors L; Dybedal I; Garelius H; Grovdal M; Dufva IH; Kjeldsen L; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Mollgard L; Hellstrom-Lindberg E
Conference publication: BONE MARROW TRANSPLANTATION. 2009;43:S276-S277
Chimerism analysis as a predictor of relapse of myelodysplastic syndrome after allogeneic stem cell transplantation
Tobiasson M; Olsson R; Remberger M; Hellstrom-Lindberg E; Mattsson J
Visa fler

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, hematologi, Karolinska Institutet, 2022
Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2015

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI